January 18, 1998 |
In one laboratory hallway at Geron Corp., a Bay Area biotech firm, are photos of the scientists rafting down a river together and dancing at a Christmas party. A poster advertises a company ski trip. Then, in another hallway, a different side of life there is revealed in pictures taken last summer during a round-the-clock race with competing labs to pinpoint a hotly pursued gene. A shot of the parking lot one Saturday shows cars aplenty. Desks sag under data printouts.
May 4, 2011 |
On Wednesday morning the California Institute for Regenerative Medicine announced a $25-million award to support a spinal cord injury trial. It is the first time that the $3-billion state stem cell funding agency has backed a human clinical trial. As expected by observers, the award is a loan to Geron Corp., a Menlo Park, Calif.-based biopharmaceuticals firm that has been working on a treatment for spinal cord injuries that is derived from...
October 11, 2010
Make way for the future, at least when it comes to stem-cell therapy. An Atlanta hospital treated the first patient Friday in a nationwide clinical trial of a therapy derived from embryonic stem cells. The clinical trial, run by pharmaceutical company Geron Corp., seeks to test whether experimental cells, known as GRNOPC1, are safe for use in humans and whether patients will regain neuromuscular control in their legs and torsos. The Shepherd Center in Atlanta, a rehabilitation hospital that specializes in people who have spinal cord injuries or disease, and Northwestern Medicine in Chicago are currently enrolling patients in the trial.
November 21, 2011 |
For patients paralyzed by spinal cord injuries, Geron Corp.'s stem cell research was the shining hope. The biotech firm showered scientists with millions of dollars to develop a treatment to reverse spinal damage. The therapy was the first treatment derived from embryonic stem cells to be cleared by the Food and Drug Administration for testing in humans. But last week, Geron abruptly pulled the plug on its pioneering trial and the rest of its stem cell business, including early work on treatments for heart ailments, diabetes and other diseases.
September 7, 2006 |
Geron Corp. and Advanced Cell Technology Inc. agreed to settle a patent dispute over a pioneering cloning technology that led to the creation of Dolly the sheep. Advanced Cell and the University of Massachusetts agreed to end their appeal and give up certain patents for animal cloning technology while keeping rights to a cloning method for human use, Advanced Cell said. Menlo Park, Calif.-based Geron keeps the rights to use the technology in animal cloning.
CALIFORNIA | LOCAL
November 23, 1995 |
Scientists have linked cardiovascular disease to an age-related breakdown of telomeres, repetitive strings of DNA on the ends of chromosomes. Every time a cell divides, a bit of the telomere is lost. Ultimately, when all the telomere is gone, the cells are unable to divide. Previous research has shown that cancer cells are able to prevent the telomeres from being shortened, and are thus able to continue dividing indefinitely. A team from Geron Corp. reports in the Proceedings of the National Academy of Sciences that blood vessel cells involved in atherosclerosis have shortened telomeres, suggesting that they have prematurely aged for an as-yet-unknown reason.